8 mRNA Cancer Vaccine Trials Advancing Through Global Oncology Pipelines in 2026 The United States National Cancer Institute's 2026 Annual Report to the Nation, released in January, identifies mRNA-based therapeutic vaccines as the fastest-growing category in the US oncology pipeline — with 34 active investigational new drug applications filed in the 12 months ending December 2025, a figure that has tripled since 2022 and is now drawing direct comparison to the speed of COVID-19 vaccine platform development. BioNTech and Moderna Pipeline Expansions Signal a Clinical Inflection Point Both BioNTech and Moderna have disclosed in their 2026 first-quarter regulatory filings expanded oncology pipeline programs targeting melanoma, non-small cell lung cancer, and colorectal cancer using mRNA neoantigen vaccine platforms. BioNTech's BNT111, targeting four melanoma-associated antigens, has completed its Phase II expansion cohort with overall response rate data expected mid-2026, while ...
Provides comprehensive research solutions, including customized reports and consulting, empowering clients to make informed business decisions.